FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
CureVac N.V. - Ordinary Shares
(NQ:
CVAC
)
4.660
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CureVac N.V. - Ordinary Shares
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Tesla Partner CureVac Says Will Find 'Sweet Spot' For COVID-19 Vaccine Despite Disappointing Data
↗
June 18, 2021
CureVac N.V.’s (NASDAQ: CVAC) Chief Financial Officer Pierre Kemula is optimistic its COVID-19 vaccine could still be offered to certain age groups or as a booster, the...
Via
Benzinga
Mid-Afternoon Market Update: Nasdaq Gains Over 100 Points; CureVac Shares Plummet
↗
June 17, 2021
Toward the end of trading Thursday, the Dow traded down 0.67% to 33,806.27 while the NASDAQ rose 0.91% to 14,167.03. The S&P also fell, dropping 0.02% to 4,222.94. The U.S....
Via
Benzinga
Topics
Stocks
Dow Plummets as Fed Update, Jobless Data Weighs
↗
June 17, 2021
The Federal Reserve's accelerated interest rate timeline and inflation forecast is putting a damper on stocks today, with worse-than-expected weekly jobless claims only adding insult to injury.
Via
Talk Markets
Topics
Economy
Stocks
Mid-Day Market Update: Gold Drops Over 4%; Midatech Pharma Shares Jump
↗
June 17, 2021
Midway through trading Thursday, the Dow traded down 0.35% to 33,913.86 while the NASDAQ rose 0.73% to 14,142.60. The S&P also rose, gaining 0.07% to 4,226.52. The U.S. has...
Via
Benzinga
Topics
Stocks
Why CureVac's Stock Is Trading Higher Today
↗
May 13, 2021
CureVac (NASDAQ:CVAC) shares are trading higher ...
Via
Benzinga
34 Stocks Moving In Thursday's Mid-Day Session
↗
June 17, 2021
Gainers Cellect Biotechnology Ltd. (NASDAQ: APOP) shares jumped 68.5% to $5.51 after the company announced it filed a registration statement in connect with the proposed merger...
Via
Benzinga
Why CureVac Stock Is Getting Crushed Today
↗
June 17, 2021
The biotech's COVID-19 vaccine candidate no longer appears to be viable.
Via
The Motley Fool
Mid-Morning Market Update: Markets Mixed; Kroger Earnings Top Views
↗
June 17, 2021
Following the market opening Thursday, the Dow traded down 0.29% to 33,935.28 while the NASDAQ rose 0.34% to 14,086.74. The S&P also fell, dropping 0.01% to 4,223.07. The U.S...
Via
Benzinga
Topics
Stocks
CureVac Stock Plummets After Covid Vaccine Fails In Interim Analysis
↗
June 17, 2021
CureVac stock plummeted Thursday after its messenger RNA-based Covid vaccine failed in an interim analysis. The vaccine was 47% effective against Covid of any severity.
Via
Investor's Business Daily
CVAC Stock: The Huge Covid-19 News That Has CureVac Plunging Today
↗
June 17, 2021
CureVac shares crashed after the German biotech said its Covid-19 vaccine was only 47% effective in preventing the disease.
Via
InvestorPlace
The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme
↗
June 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,...
Via
Benzinga
25 Stocks Moving in Thursday's Pre-Market Session
↗
June 17, 2021
Gainers Midatech Pharma plc (NASDAQ: MTP) rose 42.2% to $2.90 in pre-market trading after the company disclosed breakthrough data using Q-Sphera technology. Cellect...
Via
Benzinga
Tesla-Backed CureVac Plunges On Underwhelming COVID-19 Vaccine Efficacy Data
↗
June 17, 2021
German vaccine developer, CureVac N.V. (NASDAQ: CVAC), may not be as fortunate as its domestic peer BioNTech SE (NASDAQ: BNTX), which along with its...
Via
Benzinga
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
June 16, 2021
- Pivotal study conducted in 10 countries in fast changing environment of at least 29 COVID-19 variant strains; original strain almost completely absent - At second interim analysis, statistical...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Unusual Options Activity Insight: CureVac
↗
June 16, 2021
CureVac (NASDAQ:CVAC) shares experienced unusual options activity on Wednesday. The stock price moved up to $99.74 following the option alert. Sentiment: BULLISH Option Type:...
Via
Benzinga
Moderna, BioNTech Pop Despite Mounting Pressure On Covid Vaccine Patents
↗
June 10, 2021
The World Trade Organization is moving ahead with a plan that could waive Covid vaccine patents. But vaccine stocks weren't rattled Thursday.
Via
Investor's Business Daily
Topics
Intellectual Property
75 Biggest Movers From Yesterday
↗
June 09, 2021
Gainers Clover Health Investments, Corp. (NASDAQ: CLOV) shares surged 85.8% to close at $22.15 on Tuesday amid increased retail investor interest in the stock. NextDecade...
Via
Benzinga
Mid-Morning Market Update: Markets Mixed; Thor Industries Beats Q3 Estimates
↗
June 08, 2021
Following the market opening Tuesday, the Dow traded down 0.16% to 34,574.38 while the NASDAQ rose 0.32% to 13,926.79. The S&P also fell, dropping 0.04% to 4,224.95. The U.S....
Via
Benzinga
Topics
Stocks
50 Stocks Moving In Tuesday's Mid-Day Session
↗
June 08, 2021
Gainers Clover Health Investments, Corp. (NASDAQ: CLOV) shares jumped 72.4% to $20.55 amid increased retail investor interest in the stock. NextDecade Corporation (NASDAQ: NEXT...
Via
Benzinga
Could CureVac Be a Millionaire-Maker Stock?
↗
June 08, 2021
This biotech's coronavirus vaccine candidate could be the next to hit the market -- but a lot of its potential success has been priced in.
Via
The Motley Fool
CureVac Appoints Klaus Edvardsen as Chief Development Officer
June 02, 2021
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE /June 2, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
CureVac's COVID-19 Vaccine Is Safe, But Efficacy Not Yet Disclosed
↗
June 01, 2021
CureVac BV (NASDAQ: CVAC) said its first-generation COVID-19 vaccine candidate had passed its first interim analysis, but it was not yet ready to share efficacy data....
Via
Benzinga
CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
May 28, 2021
- Study continues to progress according to protocol following first interim analysis at 59 eligible COVID-19 cases - Sequencing data to be made available in parallel with efficacy data given...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates
May 26, 2021
- First-Generation COVID-19 vaccine program, CVnCoV - Phase 3 trial started with CVnCoV in adults suffering from selected comorbidities - Phase 2a trial in Peru and Panama assessing third booster...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
The Battle Over Covid Vaccine Patents Begins — What It Could Mean For Biotech
↗
May 20, 2021
Experts say a patent waiver for coronavirus shots wouldn't just pressure Covid vaccine stocks, it could also staunch innovation for biotech companies.
Via
Investor's Business Daily
Topics
Intellectual Property
CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study
↗
May 13, 2021
CureVac N.V. (NASDAQ: CVAC) and GlaxoSmithKline Plc (NYSE: GSK) have released positive early data from a preclinical study of its second-...
Via
Benzinga
CureVac: Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study
May 13, 2021
- Second-generation lead COVID-19 vaccine candidate, CV2CoV, developed in collaboration by CureVac and GSK - CV2CoV mRNA shows high levels of antigen production in rat model - Fast onset of strong...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
What's Up WIth BioNTech Stock And CureVac Stock Today?
↗
May 10, 2021
BioNTech SE - ADR (NASDAQ: BNTX) shares were trading higher by 8.27% at $198.80 in Monday’s premarket session after the company announced a Chinese joint venture to...
Via
Benzinga
70 Biggest Movers From Friday
↗
May 10, 2021
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday. Velocity Financial, Inc. (NYSE: VEL) rose 36.6% to close at $12.50 following Q1...
Via
Benzinga
Week In Review: WHO Close To Approving Global Use For Two China COVID-19 Vaccines
↗
May 08, 2021
The World Health Organization approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the pandemic. Sinovac's inactivated COVID-19 vaccine...
Via
Talk Markets
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
